Neurology

This approval comes after the drug was found to be safe and effective in 2 randomized, double-blind, placebo-controlled trials including 655 adults with partial-onset seizures.

After a clinical trial showed the treatment was more effective than placebo, the FDA approved the first treatment for episodic cluster headache in adults that reduces the frequency of attacks.

The medication is to be used as an adjunctive therapy in adult and pediatric patients with complex partial seizures.

The FDA has released a warning about the potential for an increase in disability in patients with multiple sclerosis who stop taking this immunosuppressant.

The new humanized monoclonal antibody acts by reducing the effect of CGRP, which is believed to have a physiologic role in migraine.

The FDA has approved a new migraine injection available in weekly and monthly dosing options.

The FDA has approved a new drug for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.

The US Food and Drug Administration has granted approval to the first treatment in a new drug class for a nerve condition that affects about 50,000 people worldwide.

Following the success of 3 clinical trials, the US Food and Drug Administration granted approval to a once-monthly, self-injectable preventive treatment for adults with migraine.

Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy. ...